

2023 Day at the Capitol Volunteer Cheat Sheet

SB 344 (Rubio) California Cancer Registry– CO-SPONSOR

- The California Cancer Registry, established in 1985, is the largest cancer registry in the nation and is recognized as one of the leading cancer registries in the world.
- The CCR is an integrated surveillance program comprised of physicians and treatment facilities that collect and report cancer data, CCR staff who receive the data and ensure accuracy, and researchers who use CCR data to make new discoveries about cancer diagnosis, patterns, and treatment outcomes.
- The cancer data collected by the CCR helps researchers understand the causes of cancers and how to prevent and treat cancers.
- The CCR regularly publishes reports on the cancer burden and disparities among the diverse populations in California.
- Since 2019, California requires pathologists to report cancer data electronically to the CCR. Direct electronic pathology (e-Path) reporting into cancer registries has helped improve the completeness, timeliness, quality, and impact of cancer registry data. *However, changes are needed to update the CCR and make it more efficient.*
- SB 344 will improve the effectiveness of the California Cancer Registry by shortening delays in research and streamlining ePath reporting. SB 344 will also align California data sharing requirements with national data sharing standards to reduce the duplication and administrative burdens.

SB 421 (Limón) Oral Chemotherapy Fairness – CO-SPONSOR

- In California, there are 178,000 new cancer cases that are reported within a year.
- The emergence of safe, clinically-effective, orally-administered anticancer medications has dramatically improved the quality of life for cancer patients.
- Patients have been routinely charged significantly greater out-of-pocket costs for oral anticancer therapies than traditional IV therapies.
- Since 2013, state law has placed a \$250 per month cap on the out-of-pocket costs for oral anticancer medication. This law is set to sunset on January 1, 2024.
- Since this cap was instituted in state law, 43 states and Washington, DC, have passed oral oncology fairness laws.
- Passage of these laws has made therapies more accessible and equitable to marginalized communities that face greater disparities.
- Senate Bill 421 removes the sunset date, making the cap on out-of-pocket costs to \$250 permanent and maintaining affordability for cancer patients.

SB 496 (Limón) Biomarker Testing – CO-SPONSOR

- SB 496 (Limón) will require all health plans and insurers, including Medi-Cal Managed Care plans, to cover biomarker testing for all stages of disease.
- Precision medicine is dramatically improving cancer outcomes by using information about a person's own genes or proteins (biomarkers) to prevent, diagnose, or treat disease.
- Biomarkers are the biological molecules found in blood, tissues, or other bodily fluids that provide insight into medical conditions and diseases.
- Biomarker testing is a way of looking for genes, proteins, and other substances that provide information about a cancer.
- This is important because it means that through biomarker testing, we can align the right treatment to the right patient at the right time. Without it, we will continue to address cancer in a way that impacts the entire body and does not always cure the cancer.
- SB 496 (Limón) will ensure patients receive the right treatment at the right time.